

# Joyce Sanders

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2658781/publications.pdf>

Version: 2024-02-01

21  
papers

957  
citations

840776

11  
h-index

752698

20  
g-index

21  
all docs

21  
docs citations

21  
times ranked

2726  
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017, 49, 1767-1778.	21.4	289
2	An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer. <i>Nature Medicine</i> , 2021, 27, 1250-1261.	30.7	159
3	Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes. <i>Breast Cancer Research</i> , 2019, 21, 90.	5.0	81
4	Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, <i>BRCA1</i> -like status, tumor-infiltrating immune cells and survival. <i>Oncolmmunology</i> , 2018, 7, e1509820.	4.6	80
5	Androgen receptor signalling in macrophages promotes TREM-1-mediated prostate cancer cell line migration and invasion. <i>Nature Communications</i> , 2020, 11, 4498.	12.8	66
6	The Prognostic Value of Immune Factors in the Tumor Microenvironment of Penile Squamous Cell Carcinoma. <i>Frontiers in Immunology</i> , 2018, 9, 1253.	4.8	61
7	Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis. <i>BMC Medicine</i> , 2015, 13, 156.	5.5	51
8	Optimized ChIP-seq method facilitates transcription factor profiling in human tumors. <i>Life Science Alliance</i> , 2019, 2, e201800115.	2.8	41
9	Molecular characterization of colorectal adenomas reveals POFUT1 as a candidate driver of tumor progression. <i>International Journal of Cancer</i> , 2020, 146, 1979-1992.	5.1	32
10	Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence. <i>Cancer Discovery</i> , 2022, 12, 2074-2097.	9.4	22
11	Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab010.	2.9	21
12	Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ. <i>Npj Breast Cancer</i> , 2021, 7, 31.	5.2	11
13	Copy number profiling by array comparative genomic hybridization identifies frequently occurring <i>BRCA</i> -like male breast cancer. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 734-744.	2.8	10
14	Expression of the immune modulator secretory leukocyte protease inhibitor (SLPI) in colorectal cancer liver metastases and matched primary tumors is associated with a poorer prognosis. <i>Oncolmmunology</i> , 2020, 9, 1832761.	4.6	10
15	The prognostic value of the interferon-gamma (IFN $\gamma$ ) signature in patients with macroscopic stage III melanoma treated with and without adjuvant systemic therapy. <i>Journal of Clinical Oncology</i> , 2021, 39, 9579-9579.	1.6	5
16	Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk. <i>British Journal of Cancer</i> , 0, , .	6.4	5
17	High expression of secretory leukocyte protease inhibitor (SLPI) in stage III micro-satellite stable colorectal cancer is associated with reduced disease recurrence. <i>Scientific Reports</i> , 2022, 12, .	3.3	5
18	Concurrent Radiotherapy and Panitumumab after Lymph Node Dissection and Induction Chemotherapy for Invasive Bladder Cancer. <i>Journal of Urology</i> , 2019, 201, 478-485.	0.4	4

#	ARTICLE	IF	CITATIONS
19	Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium. <i>The Clinical Journal of Pathology</i> , 2014, , n/a-n/a.	0.0	2
20	IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women. <i>Npj Breast Cancer</i> , 2021, 7, 138.	5.2	1
21	Immune landscape of breast tumors with low and intermediate estrogen receptor (ER) expression.. <i>Journal of Clinical Oncology</i> , 2022, 40, 566-566.	1.6	1